[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN112891310A - Preparation method of cannabidiol powder, cannabidiol powder prepared by preparation method and application of cannabidiol powder - Google Patents

Preparation method of cannabidiol powder, cannabidiol powder prepared by preparation method and application of cannabidiol powder Download PDF

Info

Publication number
CN112891310A
CN112891310A CN201911222258.5A CN201911222258A CN112891310A CN 112891310 A CN112891310 A CN 112891310A CN 201911222258 A CN201911222258 A CN 201911222258A CN 112891310 A CN112891310 A CN 112891310A
Authority
CN
China
Prior art keywords
cannabidiol
powder
excipient
emulsifier
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911222258.5A
Other languages
Chinese (zh)
Inventor
高伟
焦丽娟
徐建中
任婷婷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chenguang Biotech Group Co Ltd
Original Assignee
Chenguang Biotech Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chenguang Biotech Group Co Ltd filed Critical Chenguang Biotech Group Co Ltd
Priority to CN201911222258.5A priority Critical patent/CN112891310A/en
Publication of CN112891310A publication Critical patent/CN112891310A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides a preparation method of cannabidiol powder, which is prepared from cannabidiol oil, an emulsifier and a biologically acceptable carrier or excipient, wherein the cannabidiol powder with a specific combination form and a microstructure is obtained by compounding the emulsifier, the biologically acceptable carrier or excipient in a certain way, so that the problem that cannabidiol is insoluble in water is solved, the cannabidiol powder has good dispersibility in water, and the obtained water dispersion system achieves good uniform stability; and the obtained cannabidiol powder product has good stability and is convenient to store and use.

Description

Preparation method of cannabidiol powder, cannabidiol powder prepared by preparation method and application of cannabidiol powder
Technical Field
The invention belongs to the field of preparation and application, and relates to a preparation method of cannabidiol powder for improving water solubility, cannabidiol powder prepared by the method and application of the cannabidiol powder.
Background
Cannabidiol is a natural active ingredient from the stem, leaf and seed of an annual herb plant cannabis sativa of cannabis, cannabinaceae, has various pharmacological activities, has therapeutic effects on neurodegenerative diseases such as epilepsy, inflammation, alzheimer's disease, Multiple Sclerosis (MS), parkinson's disease, amyotrophic lateral sclerosis and the like, has therapeutic and relief effects on psychiatric diseases such as schizophrenia, depression, anxiety and the like, and has remarkable advantages in analgesia. The cannabidiol has a plurality of pharmacological effects, and can be applied to various aspects such as medicines, foods, skin care products, health care products, pet products and the like to play different effects. However, since cannabidiol is a fat-soluble substance, it is very insoluble in water, usually floats on top of water, and does not form a stable water-soluble solution. And because it is insoluble in water, it is easily destroyed, broken down or cleared by the liver, resulting in reduced delivery to the subject and greatly reduced bioavailability. Therefore, the wide and superior pharmacological properties are difficult to achieve the maximum bioavailability due to the special fat-soluble property, and the application range is limited. Therefore, changing the solubility of cannabidiol in water and increasing its water solubility to increase its bioavailability are important ways to effectively utilize and further expand its application range.
CN201910559038 discloses a preparation method of a water-soluble cannabidiol clathrate (nanocapsule), and CN201910562038 discloses a preparation method of a water-soluble industrial cannabis full spectrum oil clathrate, which respectively refer to the preparation of high-purity cannabidiol crystals and oil of a full spectrum into water-soluble clathrate. CN201910608919 discloses a preparation method of a water-soluble cannabidiol facial mask, wherein the water-soluble cannabidiol is also subjected to inclusion of cannabidiol after a cyclodextrin solution is mixed with a dispersion liquid of cannabidiol, and then a solvent and water are removed. The inclusion compound is mainly combined by utilizing Van der Waals force or hydrogen bond of cyclodextrin and cannabidiol, but the water solubility of the obtained water-soluble cannabidiol and the stability of the obtained water solution are limited, and the simple cyclodextrin inclusion compound is unstable to acid, is easy to acid decomposition and has certain limitation on the application range.
CN201910279831 discloses a cannabinoid nanoemulsion comprising a cannabidiol cyclodextrin phospholipid complex, an oil phase, a surfactant, a co-surfactant and water for improving bioavailability. The cannabidiol cyclodextrin phospholipid complex is obtained by stirring and mixing cannabidiol, phospholipid and cyclodextrin in an organic solvent and then removing the organic solvent. The obtained cannabinoid nanoemulsion exists in the form of emulsion and is inconvenient to store and transport, and the cannabidiol cyclodextrin phospholipid complex prepared by the cannabinoid nanoemulsion cannot play the role of phospholipid and cyclodextrin due to the preparation process, so that the water solubility of the obtained complex is insufficient.
CN201910608919 discloses a method for preparing cannabidiol CBD nanoemulsion freeze-dried powder, which comprises dissolving cannabidiol in an oil phase, adding an emulsifier and an auxiliary emulsifier, then adding water to form an emulsion, then adding an aqueous solution of a freeze-drying protective agent, and performing pre-freezing, sublimating, resolving and other steps to obtain a freeze-dried product. CN201480066657 discloses a compressed tablet comprising granules comprising: cannabidiol, sucrose fatty acid monoester, lactose and excipient. The granulation is produced by combining a lactose powder with a granulation fluid, the granulation fluid being a granulation produced by removing an organic solvent comprising a solution of cannabidiol, sucrose fatty acid monoesters, an antioxidant and optionally excipients in the organic solvent. WO2017183011a1 discloses a water-soluble inclusion complex comprising a cannabinoid component and β -cyclodextrin, the inclusion complex being formed into a composition with a pharmaceutically acceptable carrier and optionally a phospholipid or surfactant, for the preparation of the inclusion complex it is disclosed that the cannabinoid is melted and added to the cyclodextrin in liquid form and the two components are mixed until the inclusion complex is formed, cooling gradually will result in solidification into a dry powder, and industrial gas dryers and spray dryers can also be used to obtain solids. WO2019172876a1 discloses a water soluble phytocannabinoid emulsion formulation comprising: vegetable cannabinoids oil; and a nonionic surfactant, and the ratio of the two is defined. And that emulsions may be formulated by mixing the phytocannabinoid compound with a particular fatty acid mixture.
On the basis of the above prior art, there is still a need to further simplify the process flow and further improve the water solubility. The invention aims to improve the water solubility and stability of cannabidiol, expand the application range of cannabidiol, and can be applied to food, beverage, skin care products and the like.
Disclosure of Invention
In view of the technical problems still existing in the prior art, the inventors of the present invention found that by using the method for preparing cannabidiol powder described in the present application, through adding the emulsifier in the manner and adding the biologically acceptable carrier or excipient in the manner, cannabidiol powder with a specific combination shape and microstructure can be obtained, the problem that cannabidiol is insoluble in water is solved, the cannabidiol has good dispersibility in water, and the obtained water dispersion system achieves good uniform stability; and the obtained cannabidiol powder product has good stability and is convenient to store and use.
The "cannabidiol powder" described herein is a powdery substance prepared from a full spectrum of cannabis oil as a raw material and containing cannabinoids in addition to cannabidiol, wherein the content of cannabidiol is 50% or more of the total mass of all cannabinoids. The aqueous solution of cannabidiol powder, or dispersion of cannabidiol powder dispersed in water as described herein, means that the resulting dispersion is "clear", i.e., contains no macroscopic particles (e.g., undissolved lipophilic compound particles) therein, or does not include visible large micelles (macroscopic micelles) in water ". "Cannabidiol (CBD)" refers to a cannabidiol compound. The resulting solution can be visually inspected for colloids or particles to determine the extent of dissolution of the compound. Alternatively, the solution may be filtered and analyzed to determine solubility. For example, a spectrophotometer may be used to determine the concentration of a compound present in the filtered solution. Typically, the test solution is compared to a positive control containing a series of known amounts of a pre-filtered lipophilic natural compound solution to obtain a standard concentration versus UV/VIS absorbance curve. Alternatively, the amount of compound in solution can be determined using high performance liquid chromatography.
Specifically, the method is realized by the following technical scheme:
a method for preparing a powder from cannabidiol oil, an emulsifier and a biologically acceptable carrier or excipient, comprising the steps of:
(1) the cannabidiol oil and the emulsifier are melted at the temperature of 50-80 ℃ to form a molten liquid;
(2) adding a biologically acceptable carrier or excipient into 70% -100% ethanol for dissolving to form a carrier or excipient solution;
(3) mixing the molten liquid with the excipient solution to obtain a uniform emulsion, and drying the mixed solution under reduced pressure to obtain cannabidiol powder;
or the preparation process comprises the following steps:
(1) dissolving cannabidiol oil and an emulsifier in 70% -100% ethanol to form a mixed solution (I);
(2) adding a biologically acceptable carrier or excipient into water to dissolve to form a carrier or excipient dispersion liquid;
(3) mixing the liquid obtained in the step (1) and the liquid obtained in the step (2) to obtain a uniform emulsion, and performing spray drying to obtain cannabidiol powder;
or the preparation process comprises the following steps:
(1) the cannabidiol oil and the emulsifier are melted at the temperature of 50-80 ℃ to form a molten liquid;
(2) adding a biologically acceptable carrier or excipient into water to dissolve to form a carrier or excipient solution; and
(3) mixing the liquid obtained in the step (1) and the liquid obtained in the step (2) to obtain a uniform emulsion, and performing spray drying to obtain cannabidiol powder;
the order of steps (1) and (2) in any of the above-described manufacturing processes may be interchanged.
Or, a preparation method of the powder, which comprises the following steps:
(1) dissolving cannabidiol oil in 70% -100% ethanol to obtain a solution;
(2) adding a biologically acceptable carrier or excipient into the solution obtained in the step (1), and mixing to obtain a mixed solution;
(3) drying the mixed solution obtained in the step (2) under reduced pressure to obtain a solid;
(4) and (4) dissolving the solid obtained in the step (3) in water, adding an emulsifier, mixing, shearing, emulsifying, and spray-drying to obtain cannabidiol powder.
The cannabidiol oil is from full spectrum cannabidiol oil, the content of Cannabidiol (CBD) is more than or equal to 50 wt%, and the content of Cannabidivarin (CBDV) is less than or equal to 40 wt%.
The emulsifier comprises: one or more of sucrose fatty acid ester, polyvinyl alcohol, polyoxyethylene sorbitan fatty acid ester, mono-diglycerol fatty acid ester, phospholipid and poloxamer 188; preferably, the emulsifier is selected from one or two of phospholipid and sucrose fatty acid ester.
The carrier or excipient comprises: one or more of modified starch, Arabic gum, gelatin, sodium caseinate, cyclodextrin, alcohol soluble protein and polyvinylpyrrolidone; preferably, the carrier or excipient is one or a combination of more than two of modified starch, cyclodextrin and polyvinylpyrrolidone.
The additive amount of the carrier or excipient is 35 wt% -90 wt%, preferably 40 wt% -85 wt%, more preferably 50 wt% -80 wt%, and most preferably 60 wt% -75 wt% based on the total mass of the cannabidiol oil, the emulsifier and the biologically acceptable carrier or excipient.
The additive amount of the emulsifier is 3 wt% -50 wt%, preferably 5 wt% -40 wt%, more preferably 6 wt% -25 wt%, and most preferably 8 wt% -15 wt% based on the total mass of the cannabidiol oil, the emulsifier and the biologically acceptable carrier or excipient.
The step (3) is mixed by shearing, and the mixing time is 0.5 to 10 hours, preferably 1 to 6 hours, and more preferably 1.5 to 4 hours.
The invention also provides cannabidiol powder prepared by the preparation method of the powder.
In the resulting cannabidiol powder, the Cannabidiol (CBD) content is between 3% and 30%, preferably between 4 and 20%, more preferably between 5 and 15%, most preferably between 6 and 12% by weight of the total cannabidiol powder.
The resulting cannabidiol powder has a powder bulk density of 0.3-0.8g/mL, as determined by the funnel method.
The obtained cannabidiol powder is particles having an average size of 20 μm to 2000 μm.
The obtained cannabidiol powder forms an aqueous dispersion (1% or less) of powder mass concentration of 1% or less, having an absolute value of zeta potential of > 30. Cannabidiol powder comprising cannabidiol oil, an emulsifier and a biologically acceptable carrier or excipient as raw materials, having a Cannabidiol (CBD) content of 3% to 30%, preferably 4% to 20%, more preferably 5% to 15%, most preferably 6% to 12% by total mass; the addition amount of the emulsifier is 3-50 wt%, preferably 5-40 wt%, more preferably 6-25 wt%, and most preferably 8-15 wt%; the content of the carrier or excipient is 35 wt% -90 wt%, preferably 40 wt% -85 wt%, further preferably 50 wt% -80 wt%, and most preferably 60 wt% -75 wt%; the cannabidiol powder has an average size of 20-2000 μm and has a powder bulk density of 0.3-0.8 g/mL. Preferably, the cannabidiol powder has an average size of 30-1800 μm, more preferably 50-1000 μm.
The invention also provides an aqueous dispersion prepared from the cannabidiol powder, which is characterized in that the aqueous dispersion is prepared by dispersing the cannabidiol powder in water, and the absolute value of zeta potential of the aqueous dispersion with the powder mass percentage concentration less than or equal to 1% is more than 30.
The dispersed cannabidiol powder particles in the aqueous dispersion have an average particle size of 1-500 nm.
The invention also relates to the application of the cannabidiol powder or the cannabidiol water dispersion liquid in food, beverage, skin care products and medicines.
The skin care product comprises one or more of cleansing milk, moisturizing milk, essence cream, face cream, eye cream, facial mask and sunscreen cream.
The application comprises adding Cannabidiol (CBD) powder in an amount of 5-5000 ppm.
The present invention also relates to a food, a drink, a skin care product or a pharmaceutical product containing the cannabidiol powder or the aqueous dispersion.
In some embodiments, Cannabidiol (CBD) may be present in the aqueous dispersion at a concentration of at least 0.01 wt%, 0.05%, 0.1%, 0.2%, 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 4.0%, or 5.0% by weight. In some embodiments, the concentration of cannabidiol powder in the aqueous dispersion may be, for example, from 0.01% to 80%, from 0.1% to 80%, from 1% to 80%, from 5% to 50%, from 10% to 35%, or from 20% to 25% by weight.
At least 0.5mg, 1mg, 2mg, 3mg, 4mg, 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 100mg, 200mg, 300mg, 400mg, 500mg or 1g of the Cannabidiol (CBD) is present in a water-based food, beverage, skin care product or pharmaceutical product. In other embodiments, the Cannabidiol (CBD) is present in a food, beverage, skin care product or pharmaceutical product in an amount of 0.1mg to 2g, 0.5mg to 1g, 1mg to 500mg, 1mg to 100mg, 1mg to 50mg, 1mg to 10mg or 1mg to 5 mg. The Cannabidiol (CBD) is introduced by adding the cannabidiol powder or the aqueous dispersion.
According to the invention, a certain emulsifier is combined with a biologically acceptable carrier or excipient, and the substances are compounded by adopting a specific preparation method to prepare the cannabidiol powder with a specific combination form and a microstructure, so that the solubility of the cannabidiol in water is improved, and the application range of the cannabidiol is expanded. The invention has the following beneficial effects:
(1) the method has simple process and lower cost and is convenient for realizing industrial production;
(2) the cannabidiol powder prepared by the method has good content stability, the aluminium foil bags are packed in a non-vacuum mode for 6 months under the conditions of 40 ℃ and 75% RH in an accelerated test, the cannabidiol content retention rate is greater than 90%, and further greater than 90.5%, preferably greater than 91%, and the cannabidiol powder is convenient to store and use;
(3) the cannabidiol powder product has uniform particles and high powder bulkiness, so that the solubility of the cannabidiol powder product is obviously improved, and meanwhile, the dissolving speed of the cannabidiol powder product is far higher than that of the existing water-soluble cannabidiol product, so that the application efficiency is improved; meanwhile, the cannabidiol powder has good stability when dispersed in water, and the absolute value of zeta potential is more than 30.
Detailed Description
The present invention is further illustrated by the following specific examples, but the present invention is not limited to these examples, and the examples should not be construed as limiting the present invention.
The bulk density of the powder according to the invention is determined by the funnel method, i.e. the cannabidiol powder obtained is allowed to fall freely from the funnel opening at a height which is set in the invention to 20cm and filled into the cup.
Respectively and accurately measuring cannabidiol powder (dosage is 1g) and dispersing in 100ml of purified water to be fully and uniformly dispersed, and measuring the granularity of the cannabidiol powder in the aqueous solution and the Zeta potential of the aqueous solution by using a Nano ZS Malvern nanometer granularity and Zeta potential analyzer.
Example 1:
(1) accurately weighing 10g of whole spectrum oil (with cannabidiol content of 50 wt%), weighing 5g of poloxamer 188, and melting in 70 deg.C water bath.
(2) 65g of hydroxypropyl β -cyclodextrin were weighed out and dissolved in 1000mL of 95% ethanol until completely dissolved.
(3) Mixing the solution prepared in the step (1) and the solution prepared in the step (2), and carrying out water bath reaction at 40 ℃ for 3 hours;
(4) drying the reaction solution under reduced pressure to obtain cannabidiol clathrate, and pulverizing to obtain powder with cannabidiol content of 6.05%.
Comparative example 1: in the above example (1), 70g of hydroxypropyl β -cyclodextrin was directly added to (2) without adding poloxamer. The other conditions were consistent. Powder was obtained and the cannabidiol content was determined to be 6.10%.
Example 2:
(1) accurately weighing 10g of cannabidiol oil (with the CBD content of 83 wt% and no THC detected), and adding 10mL of 95% ethanol for complete dissolution;
(2) 5g of sucrose fatty acid ester and 1g of phospholipid are dissolved in the solution in the step (1) and are uniformly dissolved;
(3) weighing 64g of modified starch in a 500mL beaker, adding 200mL of purified water, and uniformly heating in a water bath at 60 ℃ until the starch is completely dissolved.
(4) Adding the solution prepared in the step (2) into the solution prepared in the step (3), and shearing and emulsifying.
(5) And (3) carrying out spray drying on the emulsion which is emulsified uniformly to obtain powder, detecting that the content of cannabidiol is 10.01%, and comparing example 2: in the above embodiment, the step (2) is removed, 70g of modified starch is directly added in the step (3), the rest steps are consistent, powder is obtained, and the content of cannabidiol is detected to be 10.03%.
Example 3:
(1) 10g of cannabidiol oil (CBD content 80 wt%) was weighed out accurately and dissolved by sonication using 100mL of absolute ethanol.
(2) Weighing 50g of hydroxypropyl beta-cyclodextrin, dissolving in the solution in the step (1), and carrying out ultrasonic treatment until the hydroxypropyl beta-cyclodextrin is completely dissolved.
(3) And (3) drying the solution prepared in the step (2) under reduced pressure to obtain an inclusion compound, and crushing to obtain powder.
(4) Dissolving the prepared powder in 210mL of purified water, reacting in 70 ℃ water bath for 10min, adding 30g of sucrose ester, completely dissolving, and shearing and emulsifying.
(5) Spray drying emulsified water solution to obtain powder, and detecting cannabidiol content to be 8.62%.
Comparative example 3:
in the above example 3, the sucrose ester of the step (4) was replaced with hydroxypropyl β -cyclodextrin, and the remaining steps were identical, to obtain powder, having a cannabidiol content of 8.59%.
Example 4:
(1) accurately weighing 10g cannabidiol oil (with CBD content of 50 wt%), adding 10g poloxamer, and melting and dissolving at 70 deg.C;
(2) 60g of Arabic gum is weighed, put into a 500mL beaker, added with 200mL of purified water, uniformly heated in a water bath at 60 ℃ and completely dissolved.
(3) Adding the solution prepared in the step (2) into the solution prepared in the step (3), shearing and emulsifying, and homogenizing under the condition of 50mPa to obtain a uniform emulsion.
(4) And (4) carrying out spray drying on the emulsion in the step (3) to obtain powder, wherein the content of cannabidiol is detected to be 6.12%.
Comparative example 4:
in the above example 4 (1), poloxamer was removed, 70g of gum arabic was directly added, and the remaining steps were identical, to obtain powder, and the cannabidiol content was measured to be 6.09%.
The cannabidiol powders prepared above were dispersed in water, aqueous solutions having a concentration of 1% by mass were prepared, the states of the aqueous solutions were observed, and the median particle diameter and Zeta potential of the aqueous solutions were measured, and the results are shown in table 1:
TABLE 1
Figure BDA0002301180210000091
From the above data, it can be seen that cannabidiol powder prepared by the method of the present application has a lower particle size, an increased absolute value of potential, a more stable solution, and a clear and transparent aqueous solution.
The powders obtained in examples 1 to 4 and comparative examples 1 to 4 were tested for content stability, and accelerated testing was conducted for 6 months in non-vacuum packaging in aluminum foil bags at 40 ℃ and 75% RH, and the results of the stability data are shown in Table 2:
TABLE 2
Figure BDA0002301180210000101
From the above data, it can be seen that the cannabidiol powder prepared by the method of the present application has a specific microstructure due to specific binding of cannabidiol with emulsifiers and biologically acceptable carriers or excipients, resulting in higher retention and better stability.
Comparative example 5:
(1) accurately weighing 10g of whole spectrum oil (with cannabidiol content of 50%), weighing 70g of poloxamer 188, and melting in 70 deg.C water bath.
(2) The melt was dissolved in 1000mL of 95% ethanol until it was completely dissolved.
(3) Reacting the solution prepared in the step (2) in water bath at 40 ℃ for 3 h;
(4) drying the reaction solution under reduced pressure to obtain a viscous paste-like substance, and cooling to obtain a soft white solid, but the powdery product cannot be obtained.
Comparative example 6:
(1) 60g of Arabic gum is weighed, placed in a 500mL beaker, added with 10g of cannabidiol oil (CBD 50%) and 10g of poloxamer, added with 200mL of purified water, uniformly heated in a 60 ℃ water bath, and mixed.
(2) The solution is cut and emulsified, and the cannabidiol oil is found to float on the surface of the solution, cannot form uniform emulsion with Arabic gum and poloxamer, and cannot be sprayed to form a powder product.
Comparative example 7:
(1) 60g of acacia gum is weighed into a beaker, 10g of cannabidiol oil (with a CBD content of 50 wt%) and 10g of poloxamer are added, 1000mL of ethanol is added, and the mixture is stirred and mixed evenly.
(2) And shearing and mixing the solution to obtain a uniform mixed solution, and performing spray drying to form a powder product. The content was found to be 6.13%.
Comparative example 8:
(1) 64g of modified starch was weighed, and 10g of cannabidiol oil (CBD content 83 wt%, THC not detected) and 5g of sucrose fatty acid ester and 1g of phospholipid were added to a beaker, and 1000mL of ethanol was added thereto, followed by uniform stirring and mixing.
(2) And shearing and mixing the solution to obtain a uniform mixed solution, and performing spray drying to form a powder product. The content was found to be 10.19%.
1g of the powder product and the corresponding water were added in accordance with the preparation of an aqueous solution having a concentration of 1% by mass, and the powder products obtained in comparative example 7 and comparative example 8 were dispersed in water, the states of the aqueous solutions were respectively prepared and observed, and the median particle diameter and Zeta potential of the aqueous solutions were measured, and the results are shown in Table 3:
TABLE 3
Figure BDA0002301180210000111
The powders obtained in comparative examples 7 and 8 were subjected to the content stability test according to the above method, and the accelerated test was carried out under the conditions of 40 ℃ and 75% RH in a non-vacuum packaging bag for 6 months, and the stability data test results are shown in Table 4:
TABLE 4
Figure BDA0002301180210000121
The above results show that compared to other preparation methods, the cannabidiol powder obtained by the method described herein gives an aqueous solution with a lower particle size, an increased absolute value of the potential, a more stable solution, and a clear and transparent aqueous solution. The obtained cannabidiol powder has higher retention rate and better stability.
Application example 1: the cannabidiol powder obtained in example 1 was directly added to the emulsion base solution in an amount of 1g/100ml, and mixed well to obtain CBD emulsion.
Application example 2: the cannabidiol powder obtained in example 2 was added directly to the brewed coffee in an amount of 0.05g/100ml, or the cannabidiol powder was mixed directly with instant coffee in an amount of 0.2g/100g to obtain CBD coffee. It can also be used in milk tea, cola, beer, etc.
Application example 3: the cannabidiol powder obtained in example 3 was added directly to a cosmetic liquid base in an amount of 0.5g/100ml to prepare CBD water.
Application example 4: the cannabidiol powder obtained in example 4 was directly added to the facial cleanser in an amount of 2g/100ml to prepare a CBD facial cleanser with anti-inflammatory and anti-acne effects.
During the application process, the cannabidiol powder prepared by the application examples 1-4 has good water solubility, good dissolution speed and wide application fields.
The above description of the embodiments is only intended to facilitate the understanding of the method of the invention and its core idea. It should be noted that, for those skilled in the art, it is possible to make various improvements and modifications to the present invention without departing from the principle of the present invention, and those improvements and modifications also fall within the scope of the claims of the present invention.

Claims (20)

1. A method for preparing a powder from cannabidiol oil, an emulsifier and a biologically acceptable carrier or excipient, comprising the steps of:
(1) the cannabidiol oil and the emulsifier are melted at the temperature of 50-80 ℃ to form a molten liquid;
(2) adding a biologically acceptable carrier or excipient into 70% -100% ethanol for dissolving to form a carrier or excipient solution;
(3) mixing the molten liquid with the excipient solution to obtain a uniform emulsion, and drying the mixed solution under reduced pressure to obtain cannabidiol powder;
or the preparation process comprises the following steps:
(1) dissolving cannabidiol oil and an emulsifier in 70% -100% ethanol to form a mixed solution (I);
(2) adding a biologically acceptable carrier or excipient into water to dissolve to form a carrier or excipient dispersion liquid;
(3) mixing the liquid obtained in the step (1) and the liquid obtained in the step (2) to obtain a uniform emulsion, and performing spray drying to obtain cannabidiol powder;
or the preparation process comprises the following steps:
(1) the cannabidiol oil and the emulsifier are melted at the temperature of 50-80 ℃ to form a molten liquid;
(2) adding a biologically acceptable carrier or excipient into water to dissolve to form a carrier or excipient solution; and
(3) mixing the liquid obtained in the step (1) and the liquid obtained in the step (2) to obtain a uniform emulsion, and performing spray drying to obtain cannabidiol powder;
the order of steps (1) and (2) in any of the above-described manufacturing processes may be interchanged.
2. A preparation method of powder comprises the following steps:
(1) dissolving cannabidiol oil in 70% -100% ethanol to obtain a solution;
(2) adding a biologically acceptable carrier or excipient into the solution obtained in the step (1), and mixing to obtain a mixed solution;
(3) drying the mixed solution obtained in the step (2) under reduced pressure to obtain a solid;
(4) and (4) dissolving the solid obtained in the step (3) in water, adding an emulsifier, mixing, shearing, emulsifying, and spray-drying to obtain cannabidiol powder.
3. A process for the preparation of a powder according to any one of claims 1-2 wherein the cannabidiol oil is derived from the whole spectrum of cannabis oil, has a Cannabidiol (CBD) content of 50 wt% or more and a Cannabidivarin (CBDV) content of 40 wt% or less.
4. A process for the preparation of a powder according to any of claims 1 to 3, wherein the emulsifier comprises: one or more of sucrose fatty acid ester, polyvinyl alcohol, polyoxyethylene sorbitan fatty acid ester, mono-diglycerol fatty acid ester, phospholipid and poloxamer 188; preferably, the emulsifier is selected from one or two of phospholipid and sucrose fatty acid ester.
5. A process for the preparation of a powder according to any of claims 1 to 4, wherein the carrier or excipient comprises: one or more of modified starch, Arabic gum, gelatin, sodium caseinate, cyclodextrin, alcohol soluble protein and polyvinylpyrrolidone; preferably, the carrier or excipient is one or a combination of more than two of modified starch, cyclodextrin and polyvinylpyrrolidone.
6. A process for the preparation of a powder according to any one of claims 1 to 6 wherein the carrier or excipient is added in an amount of 35 to 90 wt%, preferably 40 to 85 wt%, more preferably 50 to 80 wt%, most preferably 60 to 75 wt% based on the total mass of cannabidiol oil, emulsifier and biologically acceptable carrier or excipient.
7. A process for the preparation of a powder according to any one of claims 1 to 6 wherein the emulsifier is added in an amount of 3 wt% to 50 wt%, preferably 5 wt% to 40 wt%, more preferably 6 wt% to 25 wt%, most preferably 8 wt% to 15 wt% based on the total mass of cannabidiol oil, emulsifier and biologically acceptable carrier or excipient.
8. The method for preparing a powder according to claim 1, wherein the step (3) is carried out by shear mixing for 0.5 to 10 hours, preferably 1 to 6 hours, more preferably 1.5 to 4 hours.
9. Cannabidiol powder obtainable by a process for the preparation of a powder according to any one of claims 1 to 9.
10. Cannabidiol powder according to claim 9, wherein the cannabidiol powder is obtained with a Cannabidiol (CBD) content of 3% to 30%, preferably 4% to 20%, more preferably 5% to 15%, most preferably 6% to 12% by weight based on the total weight of the cannabidiol powder.
11. Cannabidiol powder according to claim 9, wherein the resulting cannabidiol powder has a powder bulk density of 0.3-0.8g/mL, as determined by the funnel method.
12. Cannabidiol powder according to claim 10 or 11, wherein the cannabidiol powder obtained is particles having an average size of 0.5 μ ι η -2000 μ ι η.
13. Cannabidiol powder according to claim 10 or 11, wherein the cannabidiol powder obtained forms an aqueous dispersion with a concentration of 1% by mass of the powder having an absolute value of zeta potential > 30.
14. Cannabidiol powder comprising cannabidiol oil, an emulsifier and a biologically acceptable carrier or excipient as raw materials, having a Cannabidiol (CBD) content of 3% to 30%, preferably 4% to 20%, more preferably 5% to 15%, most preferably 6% to 12% by total mass; the addition amount of the emulsifier is 3-50 wt%, preferably 5-40 wt%, more preferably 6-25 wt%, and most preferably 8-15 wt%; the content of the carrier or excipient is 35 wt% -90 wt%, preferably 40 wt% -85 wt%, further preferably 50 wt% -80 wt%, and most preferably 60 wt% -75 wt%;
the cannabidiol powder has an average size of 20-2000 μm and has a powder bulk density of 0.3-0.8 g/mL.
15. Aqueous dispersion prepared from cannabidiol powder according to any of claims 9-14, characterised in that it is prepared by dispersing cannabidiol powder in water, the aqueous dispersion having a concentration of 1% by mass of the powder having an absolute value of zeta potential > 30.
16. The aqueous dispersion of claim 15 wherein the dispersed cannabidiol powder particles in the aqueous dispersion have an average particle size of 1 to 500 nm.
17. Use of cannabidiol powder as claimed in any one of claims 9 to 14 or an aqueous dispersion as claimed in any one of claims 15 to 16 in food, beverages, skin care products and pharmaceutical products.
18. The use of claim 17, wherein the skin care product comprises one or more of a facial cleanser, a moisturizing lotion, a essence cream, a facial cream, an eye cream, a facial mask, and a sunscreen cream.
19. The use of claim 17 wherein Cannabidiol (CBD) is added to the cannabidiol powder in an amount of 5-5000 ppm.
20. A food, beverage, skin care product or pharmaceutical product comprising the cannabidiol powder of any one of claims 9 to 14 or the aqueous dispersion of any one of claims 15 to 16.
CN201911222258.5A 2019-12-03 2019-12-03 Preparation method of cannabidiol powder, cannabidiol powder prepared by preparation method and application of cannabidiol powder Pending CN112891310A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911222258.5A CN112891310A (en) 2019-12-03 2019-12-03 Preparation method of cannabidiol powder, cannabidiol powder prepared by preparation method and application of cannabidiol powder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911222258.5A CN112891310A (en) 2019-12-03 2019-12-03 Preparation method of cannabidiol powder, cannabidiol powder prepared by preparation method and application of cannabidiol powder

Publications (1)

Publication Number Publication Date
CN112891310A true CN112891310A (en) 2021-06-04

Family

ID=76104107

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911222258.5A Pending CN112891310A (en) 2019-12-03 2019-12-03 Preparation method of cannabidiol powder, cannabidiol powder prepared by preparation method and application of cannabidiol powder

Country Status (1)

Country Link
CN (1) CN112891310A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022141665A1 (en) * 2020-12-29 2022-07-07 汉义生物科技（北京）有限公司 Water-soluble cannabinoid formulation and preparation method therefor
CN114748419A (en) * 2022-03-30 2022-07-15 金林才 Water-soluble cannabidiol micro-nano emulsion and preparation method and application thereof
JP7469550B1 (en) 2022-10-21 2024-04-16 第一工業製薬株式会社 Solid composition and method for producing same

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383513B1 (en) * 1997-12-19 2002-05-07 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions comprising cannabinoids
CN101543476A (en) * 2009-05-05 2009-09-30 中山大学 A naringin solid dispersion and the preparation method, and the application thereof
US20160143972A1 (en) * 2014-11-21 2016-05-26 Cannamark Inc. Method and apparatus for preparing a solid form of cannabinoid
US20170232210A1 (en) * 2016-01-20 2017-08-17 Flurry Powders Encapsulation of lipophilic ingredients in dispensible spray dried powders suitable for inhalation
US20180271826A1 (en) * 2017-03-22 2018-09-27 Colorado Can Llc Dry powders of cannabinoids and methods for preparing dry powders
WO2018204326A1 (en) * 2017-05-01 2018-11-08 Mj Wooly Corporation Methodology and formulation for creating a powder of an encapsulated cannabis-based component embedded in a polymer matrix
CN109939014A (en) * 2017-12-20 2019-06-28 汉义生物科技（北京）有限公司 A kind of flavorants containing cannboid
CN109953951A (en) * 2019-04-09 2019-07-02 栾云鹏 A kind of cannboid nano-emulsion and preparation method thereof improving bioavilability
CN110179862A (en) * 2019-06-26 2019-08-30 云南绿新生物药业有限公司 A kind of preparation method of water solubility cannabidiol inclusion compound (Nano capsule)
US20190282502A1 (en) * 2016-01-20 2019-09-19 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
CN110279678A (en) * 2019-06-15 2019-09-27 汉义生物科技（北京）有限公司 Solid composite and its preparation method and application containing cannboid
WO2019211771A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Water soluble and water dispersible formulations of cannabinoids

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383513B1 (en) * 1997-12-19 2002-05-07 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions comprising cannabinoids
CN101543476A (en) * 2009-05-05 2009-09-30 中山大学 A naringin solid dispersion and the preparation method, and the application thereof
US20160143972A1 (en) * 2014-11-21 2016-05-26 Cannamark Inc. Method and apparatus for preparing a solid form of cannabinoid
US20170232210A1 (en) * 2016-01-20 2017-08-17 Flurry Powders Encapsulation of lipophilic ingredients in dispensible spray dried powders suitable for inhalation
US20190282502A1 (en) * 2016-01-20 2019-09-19 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
US20180271826A1 (en) * 2017-03-22 2018-09-27 Colorado Can Llc Dry powders of cannabinoids and methods for preparing dry powders
WO2018204326A1 (en) * 2017-05-01 2018-11-08 Mj Wooly Corporation Methodology and formulation for creating a powder of an encapsulated cannabis-based component embedded in a polymer matrix
CN109939014A (en) * 2017-12-20 2019-06-28 汉义生物科技（北京）有限公司 A kind of flavorants containing cannboid
WO2019211771A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Water soluble and water dispersible formulations of cannabinoids
CN109953951A (en) * 2019-04-09 2019-07-02 栾云鹏 A kind of cannboid nano-emulsion and preparation method thereof improving bioavilability
CN110279678A (en) * 2019-06-15 2019-09-27 汉义生物科技（北京）有限公司 Solid composite and its preparation method and application containing cannboid
CN110179862A (en) * 2019-06-26 2019-08-30 云南绿新生物药业有限公司 A kind of preparation method of water solubility cannabidiol inclusion compound (Nano capsule)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022141665A1 (en) * 2020-12-29 2022-07-07 汉义生物科技（北京）有限公司 Water-soluble cannabinoid formulation and preparation method therefor
CN114748419A (en) * 2022-03-30 2022-07-15 金林才 Water-soluble cannabidiol micro-nano emulsion and preparation method and application thereof
JP7469550B1 (en) 2022-10-21 2024-04-16 第一工業製薬株式会社 Solid composition and method for producing same
WO2024085054A1 (en) * 2022-10-21 2024-04-25 第一工業製薬株式会社 Solid composition and method for producing same

Similar Documents

Publication Publication Date Title
Wei et al. Fabrication and characterization of resveratrol loaded zein-propylene glycol alginate-rhamnolipid composite nanoparticles: Physicochemical stability, formation mechanism and in vitro digestion
Dai et al. Curcumin encapsulation in zein-rhamnolipid composite nanoparticles using a pH-driven method
Dai et al. Structural characterization, formation mechanism and stability of curcumin in zein-lecithin composite nanoparticles fabricated by antisolvent co-precipitation
Liu et al. Properties of curcumin-loaded zein-tea saponin nanoparticles prepared by antisolvent co-precipitation and precipitation
Wei et al. Enhanced stability, structural characterization and simulated gastrointestinal digestion of coenzyme Q10 loaded ternary nanoparticles
Mezzomo et al. Supercritical anti-solvent precipitation of carotenoid fraction from pink shrimp residue: Effect of operational conditions on encapsulation efficiency
US11278856B2 (en) Lutein microcapsule formulation and preparation method thereof
JP2015028028A (en) Method for solubilizing, dispersing, and stabilizing materials, products manufactured thereby, and use thereof
Deng et al. Tea saponins as natural emulsifiers and cryoprotectants to prepare silymarin nanoemulsion
Palazzo et al. Zein/luteolin microparticles formation using a supercritical fluids assisted technique
CN112891310A (en) Preparation method of cannabidiol powder, cannabidiol powder prepared by preparation method and application of cannabidiol powder
WO2008047559A1 (en) Highly water-dispersible powder and method of producing the same
Guan et al. The technology for improving stability of nanosuspensions in drug delivery
Poureini et al. Loading of apigenin extracted from parsley leaves on colloidal core-shell nanocomposite for bioavailability enhancement
CN108079308A (en) Ubiquinone10With the nano structured lipid carrier and preparation method of n-octacosanol compounding
Sheng et al. Preparation of quercetin nanorod/microcrystalline cellulose formulation via fluid bed coating crystallization for dissolution enhancement
JP2022509463A (en) A product composed of water-soluble particles of non-curcuminoid and water-soluble particles of curcuminoid.
Rashid et al. Nanoencapsulation of pomegranate peel extract using maltodextrin and whey protein isolate. Characterisation, release behaviour and antioxidant potential during simulated invitro digestion
CN113018266A (en) Preparation method of cannabidiol solid dispersion, cannabidiol solid dispersion prepared by preparation method and application of cannabidiol solid dispersion
CN105705623B (en) Surfactant composition
Dubey et al. Nanostructured lipid carriers of ivabradine hydrochloride: optimization, characterization and in-vivo estimation for management of stable angina
De Paz et al. Production of water-soluble quercetin formulations by antisolvent precipitation and supercritical drying
Xie et al. High resveratrol-loaded microcapsules with trehalose and OSA starch as the wall materials: Fabrication, characterization, and evaluation
US9931309B2 (en) Curcumin-sophorolipid complex
CN106256346A (en) A kind of transparent type Vitamin E acetate dry powder and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210604